PUBLISHER: DelveInsight | PRODUCT CODE: 1377972
PUBLISHER: DelveInsight | PRODUCT CODE: 1377972
“"Quadrivalent VLP vaccine Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about quadrivalent VLP vaccine for seasonal influenza in the seven major markets. A detailed picture of the quadrivalent VLP vaccine for seasonal influenza in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the quadrivalent VLP vaccine for seasonal influenza. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the quadrivalent VLP vaccine market forecast analysis for seasonal influenza in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in seasonal influenza.
Medicago is developing a quadrivalent adjuvanted virus-like particle (VLP) influenza vaccine candidate; plant-based QVLP offers an attractive alternative manufacturing method for producing effective and HA-strain-matching seasonal influenza vaccines. The QVLP vaccine is produced in Nicotiana benthamiana using the agrobacterium infiltration-based transient expression platform.
A plant-based vaccine candidate is developed from VLPs and mimics the native structure of viruses, allowing them to be recognized as such by the immune system. VLPs are purified to obtain the final material needed for vaccine manufacturing. Safety and sterility tests are performed to meet regulatory standards. An adjuvant designed to enhance the immune response may be combined with the vaccine candidate. The role of the vaccine is to help the immune system learn to recognize the targeted viruses so the body can better fight them.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Quadrivalent VLP vaccine Analytical Perspective by DelveInsight
This report provides a detailed market assessment of quadrivalent VLP vaccine for seasonal influenza in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.
The report provides the clinical trials information of quadrivalent VLP vaccine for seasonal influenza covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions